Uptrend Call Working As Chelsea Therapeutics International Stock Rises 29.6% (CHTP)
Comtex SmarTrend(R) - Fri Oct 17, 11:15AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 9 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Chelsea Therapeutics International Has Returned 29.6% Since SmarTrend Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Oct 10, 9:46AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 9 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Shares of CHTP Up 29.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Sep 25, 11:14AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 8 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Chelsea Therapeutics International Shares Up 29.6% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Thu Sep 18, 9:56AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 8 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
29.6% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Thu Sep 11, 9:36AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 8 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)
Lundbeck Completes Acquisition of Chelsea Therapeutics
Business Wire - Tue Jun 24, 9:00AM CDT
H. Lundbeck A/S (Lundbeck) today announced that it has completed its acquisition of Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) (Chelsea) for USD 6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional USD 1.50 per share upon achievement of certain sales milestones, in each case without interest and subject to any required withholding of taxes. As a result of the acquisition, Chelsea became a wholly-owned indirect subsidiary of Lundbeck, and shares of Chelsea common stock will no longer be listed on the NASDAQ Capital Market.
CHTP: 6.52 (-0.03)
Downgrade Alert for Chelsea Therapeutics International (CHTP)
Comtex SmarTrend(R) - Tue Jun 24, 6:55AM CDT
Chelsea Therapeutics International (NASDAQ:CHTP) was downgraded from Outperform to Neutral at Wedbush today. The stock closed yesterday at $6.52 on volume of 6.1 million shares, above average daily volume of 6.1 million. Chelsea Therapeutics International Ltd. is a biopharmaceutical company developing a pipeline of low toxicity antifolate compounds engineered to have anti-inflammatory and anti-tumor activity. The Company's lead candidate is in development as a metabolically inert treatment alternative to Methotrexate for rheumatoid arthritis, psoriasis, and other disorders.
CHTP: 6.52 (-0.03)
Shares of CHTP Up 31.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 23, 10:00AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 31.81% as of today's recent price of $6.63.
CHTP: 6.52 (-0.03)
NORTHERA(TM) Clinical Trial Data Published in Neurology
GlobeNewswire - Thu Jun 19, 3:30PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the publication in Neurology of its pivotal, Phase 3 study 301, a multicenter, multinational, double-blind, randomized, placebo-controlled, parallel-group study of NORTHERA (droxidopa) that details how NORTHERA demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH).
CHTP: 6.52 (-0.03)